Q3 2025 Earnings Call November 12, 2025 4:30 PM ESTCompany ParticipantsStephen From - CEO & DirectorSarah Romano - ...

Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as ...

Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204's exceptional efficacy across multiple human cancer cell ...

Running a business today demands more than just skill and passion, it requires smart, streamlined tools that make admin tasks ...

COSCIENS restructuring results in significantly lower cash outflow with operating expenses down 59% vs. Q3 2024.

You've got the spreadsheets, the apps, the color-coded categories. You're tracking every coffee, every Amazon order, every ...

Operating Cost Reduction -- Operating costs decreased by 11% ($5 million) for the quarter and $18 million or 14% year-to-date ...

Consider more than a dozen different deductions that can fatten your bottom line. Opinions expressed by Entrepreneur ...

Gross margin -- 57.9%, which declined by 250 basis points year over year because of product mix shifts and elevated ...

Brex reports that effective expense receipt tracking can streamline financial processes, reduce errors, and enhance ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 – $2.0 billion Improves 2025 expected GAAP operating ...

Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (Nasdaq: CGC) today announced its financial results for the second quarter ended September 30, 2025 ("Q2 FY2026"). All financial ...